Press Release

NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab


- The combination of NT-I7 plus pembrolizumab enhances infiltration of PD-1+ T cells



NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells in cold tumors, at the European Society for Medical Oncology (ESMO) Congress in Paris, France, September 9-13, 2022.


While initial results from the phase 2a study NIT-110 had showed that subjects responding to NT-I7 plus pembrolizumab had enhanced lymphocyte infiltration, NeoImmuneTech conducted a new biomarker analysis of the immune-associated changes in the tumor microenvironment (TME) after NT-I7 plus pembrolizumab. The overall goal was to continue to understand how the combination of the long-acting human IL-7 and a checkpoint inhibitor (CPI) can induce a stronger immune response, since CPIs alone are usually considered ineffective in cold tumors with low T cell infiltration.


New data presented in a poster at ESMO Congress 2022 suggest that the combination of NT-I7 and pembrolizumab induces infiltration of CD8 T cells into the tumor microenvironment in more than 80% of analyzed samples. The infiltration of CD8 T cells showed an increase of over 5-fold in over 50% of on-treatment samples after only one dose of NT-I7. Treatment with NT-I7 and pembrolizumab increased the immunogenicity of the TME. The analysis also revealed that treatment-induced reduction of the tumor volume was associated with the magnitude of CD8 T cell infiltration.


Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: “We continue to gather evidence to demonstrate that the combination of NT-I7 and pembrolizumab has promising clinical efficacy in very cold and immunosuppressive indications. Our latest data presented at ESMO indicate that the enhanced tumor-specific CD8 T cell infiltration into the tumor microenvironment may trigger enhanced clinical efficacy. This represents an encouraging path to potentially provide one day more therapeutic options to patients with cold tumors where CPIs are usually ineffective.”


*** ENDS ***


About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.


About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit


Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.


Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

Media inquiries :